<DOC>
	<DOC>NCT00592475</DOC>
	<brief_summary>To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.</brief_summary>
	<brief_title>A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Institutional Review Board (IRB)/Independent Ethics Committee (IEC)approved written Informed Consent and appropriate privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any studyrelated procedures (including withdrawal of prohibited medication, if applicable) Subject is euvolemic or hypervolemic (edematous) secondary to cirrhosis Subject has clinical evidence of portal hypertension by the presence of esophageal varices, ascites or both Clinical evidence of volume depletion or dehydration Subject has a history of bleeding from esophageal varices within three months before the start of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>conivaptan</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>Hypertension, Portal</keyword>
</DOC>